Toualbi Leila Azouaou, Adnane Mounir, Abderrezak Khelfi, Ballouti Wafa, Arab Medina, Toualbi Chahine, Chader Henni, Tahae Ryne, Seba Atmane
Department of Nephrology, Parnet Hospital Universite, Algiers, Algieria.
Department of Biomedicine, Institute of Veterinary Sciences, University of Tiaret, Tiaret, Algeria.
Arch Med Sci Atheroscler Dis. 2020 Sep 14;5:e245-e254. doi: 10.5114/amsad.2020.98945. eCollection 2020.
The atherosclerosis process is highly accelerated in patients with chronic kidney disease (CKD). Oxidative stress is considered as one of the pro-atherogenic factors involved in accelerating the atherosclerosis process of the carotid artery. The aim of the present study was to determine the relationship between oxidative stress markers and the progression of carotid atherosclerosis in CKD patients.
The study was conducted on 162 patients with CKD and 40 controls, and the disease stage was scored between 2 and 5D. Blood samples were taken and advanced oxidative protein product, myeloperoxidases, malondialdehyde, nitric oxide, glutathione, and oxidised low-density lipoprotein were measured. Furthermore, we studied the correlations between these biomarkers and clinical and para-clinical cardiovascular complications.
The average age of patients was 56.5 years. The oxidative stress markers average ± SD levels in CKD groups compared to the control were as follows: advanced oxidation protein product (61.89 ±1.4 vs. 26.65 ±1.05 µmol/l), myeloperoxidase (59.89 ±1.98 vs. 38.45 ±1.98 UI/ml), malondialdehyde (6.1 ±0.12 vs. 3.26 ±0.03 µmol/l), nitric oxide (65.82 ±1.06 vs. 52.19 ±2.1 µmol/l), glutathione (52.21 ±1.3 vs. 89.4 ±2.6 IU/ml), and oxLDL (15.57 ±1.07 vs. 1.72 ±0.82 µmol/l). While the glutathione level decreased significantly in advanced CKD stage ( < 0.05), the concentrations of all the other biomarkers increased significantly in accordance with CKD score ( < 0.05).
Cardiovascular diseases, mainly atherosclerosis, can be diagnosed indirectly by measuring oxidative stress markers. Furthermore, theses markers can be used to predict the progression of CKD, for better management of the disease.
慢性肾脏病（CKD）患者的动脉粥样硬化进程高度加速。氧化应激被认为是加速颈动脉动脉粥样硬化进程的促动脉粥样硬化因素之一。本研究的目的是确定氧化应激标志物与CKD患者颈动脉粥样硬化进展之间的关系。
对162例CKD患者和40例对照者进行了研究，疾病分期在2至5D之间评分。采集血样并检测晚期氧化蛋白产物、髓过氧化物酶、丙二醛、一氧化氮、谷胱甘肽和氧化型低密度脂蛋白。此外，我们研究了这些生物标志物与临床和亚临床心血管并发症之间的相关性。
患者的平均年龄为56.5岁。与对照组相比，CKD组氧化应激标志物的平均±标准差水平如下：晚期氧化蛋白产物（61.89±1.4对26.65±1.05µmol/l）、髓过氧化物酶（59.89±1.98对38.45±1.98 UI/ml）、丙二醛（6.1±0.12对3.26±0.03µmol/l）、一氧化氮（65.82±1.06对52.19±2.1µmol/l）、谷胱甘肽（52.21±1.3对89.4±2.6 IU/ml）和氧化型低密度脂蛋白（15.57±1.07对1.72±0.82µmol/l）。虽然在晚期CKD阶段谷胱甘肽水平显著降低（<0.05），但所有其他生物标志物的浓度均随CKD评分显著增加（<0.05）。
心血管疾病，主要是动脉粥样硬化，可以通过测量氧化应激标志物间接诊断。此外，这些标志物可用于预测CKD的进展，以便更好地管理该疾病。
